Skip to main content
. 2021 Dec 16;12:778204. doi: 10.3389/fimmu.2021.778204

Figure 1.

Figure 1

IFN-β levels and longitudinal assessment of serum sIFNAR2 levels in MS patients. (A) Serum IFN-β levels measured in MS patients basally and after IFN-β therapy onset (N=59). Significant p-value is shown with asterisk. (B) Graphs comparing serum sIFNAR2 levels at baseline and after 6 and 12 months of IFN-β therapy onset in two independent cohorts (Cohort 1 N=59, Cohort 2 N=35). Each point represents an individual, and horizontal bars indicate the median values and interquartile ranges. Significant p-values are shown with asterisk.